SEC Info - Cytrx Corp - ‘10-K’ for 12/31/13

Cytrx Corp – ‘10-K’ for 12/31/13 – ‘EX-31.2’

On: Tuesday, 3/4/14, at 6:18pm ET · As of: 3/5/14 · For: 12/31/13 · Accession #: 799698-14-4 · File #: 0-15327

Document/Exhibit Description Pages Size 1: 10-K Form 10-K for Fiscal Year Ending 12/31/2013 HTML 1.30M 2: EX-4.8 Instrument Defining the Rights of Security Holders HTML 46K 3: EX-10.22 Material Contract HTML 68K 4: EX-10.23 Material Contract HTML 53K 5: EX-10.24 Material Contract HTML 53K 6: EX-10.25 Material Contract HTML 52K 7: EX-10.29 Material Contract HTML 24K 8: EX-10.30 Material Contract HTML 24K 9: EX-10.31 Material Contract HTML 24K 10: EX-10.32 Material Contract HTML 26K 11: EX-23.1 Consent of Experts or Counsel HTML 22K 12: EX-31.1 Certification -- §302 - SOA'02 HTML 26K 13: EX-31.2 Certification -- §302 - SOA'02 HTML 26K 14: EX-32.1 Certification -- §906 - SOA'02 HTML 22K 15: EX-32.2 Certification -- §906 - SOA'02 HTML 22K 54: R1 Document and Entity Information HTML 49K 44: R2 Consolidated Balance Sheets HTML 95K 52: R3 Consolidated Balance Sheets (Parenthetical) HTML 48K 56: R4 Consolidated Statements of Operations HTML 70K 72: R5 Consolidated Statements of Stockholders' Equity HTML 71K 46: R6 Consolidated Statements of Cash Flows HTML 116K 51: R7 Nature of Business HTML 28K 41: R8 Summary of Significant Accounting Policies HTML 71K 33: R9 Receivables HTML 26K 73: R10 Prepaid and Other Assets HTML 23K 58: R11 Short-term Investments HTML 27K 57: R12 Equipment and Furnishings HTML 31K 62: R13 Accrued Expenses and Other Current Liabilities HTML 31K 63: R14 Warrant Liabilities HTML 36K 61: R15 Commitments and Contingencies HTML 51K 64: R16 Equity Transactions HTML 33K 53: R17 Investments in ADVENTRX Pharmaceuticals HTML 26K 55: R18 Stock Options and Warrants HTML 221K 60: R19 Sale of Assets HTML 23K 77: R20 Stockholder Protection Rights Plan HTML 25K 67: R21 Income Taxes HTML 58K 48: R22 Quarterly Financial Data (Unaudited) HTML 48K 59: R23 Subsequent Events HTML 59K 50: R24 Schedule Ii - Valuation and Qualifying Accounts HTML 40K 27: R25 Summary of Significant Accounting Policies HTML 124K (Policies) 68: R26 Summary of Significant Accounting Policies HTML 47K (Tables) 74: R27 Equipment and Furnishings (Tables) HTML 29K 37: R28 Accrued Expenses and Other Current Liabilities HTML 30K (Tables) 36: R29 Warrant Liabilities (Tables) HTML 34K 39: R30 Commitments and Contingencies (Tables) HTML 45K 40: R31 Stock Options and Warrants (Tables) HTML 218K 42: R32 Income Taxes (Tables) HTML 53K 26: R33 Quarterly Financial Data (Unaudited) (Tables) HTML 46K 65: R34 Subsequent Events (Tables) HTML 58K 47: R35 Nature of Business (Details) HTML 40K 49: R36 Summary of Significant Accounting Policies HTML 67K (Details) 30: R37 Receivables (Details) HTML 23K 76: R38 Prepaid and Other Assets (Details) HTML 23K 22: R39 Short-term Investments (Details) HTML 26K 43: R40 Equipment and Furnishings (Details) HTML 34K 71: R41 Accrued Expenses and Other Current Liabilities HTML 35K (Details) 29: R42 Warrant Liabilities (Details) HTML 41K 35: R43 Commitments and Contingencies (Details) HTML 83K 38: R44 Equity Transactions (Details) HTML 49K 45: R45 Investments in ADVENTRX Pharmaceuticals (Details) HTML 32K 25: R46 Stock Options and Warrants (Details) HTML 304K 32: R47 Sale of Assets (Details) HTML 24K 23: R48 Stockholder Protection Rights Plan (Details) HTML 33K 70: R49 Income Taxes (Details) HTML 96K 28: R50 Quarterly Financial Data (Unaudited) (Details) HTML 37K 66: R51 Subsequent Events (Details) HTML 87K 31: R52 Schedule Ii - Valuation and Qualifying Accounts HTML 32K (Details) 75: XML IDEA XML File -- Filing Summary XML 100K 24: EXCEL IDEA Workbook of Financial Reports XLSX 171K 34: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 1.26M 16: EX-101.INS XBRL Instance -- cytr-20131231 XML 1.91M 18: EX-101.CAL XBRL Calculations -- cytr-20131231_cal XML 190K 19: EX-101.DEF XBRL Definitions -- cytr-20131231_def XML 469K 20: EX-101.LAB XBRL Labels -- cytr-20131231_lab XML 1.57M 21: EX-101.PRE XBRL Presentations -- cytr-20131231_pre XML 873K 17: EX-101.SCH XBRL Schema -- cytr-20131231 XSD 162K 69: ZIP XBRL Zipped Folder -- 0000799698-14-000004-xbrl Zip 166K

I, John Y. Caloz, Chief Financial Officer of CytRx Corporation, certify that:

1. I have reviewed this annual report on Form 10-K of CytRx Corporation;

2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this annual report;

3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the periods covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 4, 2014	By:	/s/ *JOHN Y. CALOZ*
		John Y. Caloz
		Chief Financial Officer

This ‘10-K’ Filing		Date	Other Filings

Filed as of:		3/5/14	8-K
Filed on:		3/4/14	8-K
For Period end:		12/31/13
	List all Filings

This ‘10-K’ Filing

Date

Other Filings

Filed as of:

3/5/14

8-K

Filed on:

3/4/14

8-K

For Period end:

12/31/13

List all Filings

Cytrx Corp – ‘10-K’ for 12/31/13 – ‘EX-31.2’

On: Tuesday, 3/4/14, at 6:18pm ET · As of: 3/5/14 · For: 12/31/13 · Accession #: 799698-14-4 · File #: 0-15327

Previous ‘10-K’: ‘10-K’ on 3/11/13 for 12/31/12 · Next: ‘10-K’ on 3/10/15 for 12/31/14 · Latest: ‘10-K’ on 3/27/24 for 12/31/23

Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

‘EX-31.2’ — Certification — §302 – SOA’02

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

Cytrx Corp – ‘10-K’ for 12/31/13 – ‘EX-31.2’

On: Tuesday, 3/4/14, at 6:18pm ET · As of: 3/5/14 · For: 12/31/13 · Accession #: 799698-14-4 · File #: 0-15327

Previous ‘10-K’: ‘10-K’ on 3/11/13 for 12/31/12 · Next: ‘10-K’ on 3/10/15 for 12/31/14 · Latest: ‘10-K’ on 3/27/24 for 12/31/23

Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34Filing Table of Contents

‘EX-31.2’ — Certification — §302 – SOA’02

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents